OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
Investegate announcements from Galapagos NV, Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
Mechelen, Belgium; 25 April 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders' meeting (AGM)